No withdrawal; standard cardiovascular agents
This narrative does not describe a positive safety finding. Excluded from safety and setback totals.Sources (2)
- ChEMBL (EMBL-EBI)
- ClinicalTrials.gov (NIH/NLM)
Loading the evidence…
Reported safety narratives, with historical warnings and uncertain findings separated. Read the record and supporting citations before drawing conclusions.
No withdrawal; standard cardiovascular agents
This narrative does not describe a positive safety finding. Excluded from safety and setback totals.No major post-market safety failure reported
This narrative does not describe a positive safety finding. Excluded from safety and setback totals.No major post-market safety failure
This narrative does not describe a positive safety finding. Excluded from safety and setback totals.Separately FDA-approved 2024 (Aurlumyn) for severe frostbite based on a small open-label trial (n=47) - a genuine acute-injury indication distinct from this atlas entry's tested conditions
This narrative does not describe a positive safety finding. Excluded from safety and setback totals.